Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Reinaldo S. Dos Santos, Daniel Guzman-Llorens, Atenea A. Perez-Serna, Angel Nadal, Laura Marroqui

Journal title: Frontiers in Immunology

Journal number: 14

Journal publisher: Frontiers

Published year: 2023

DOI identifier: 10.3389/fimmu.2023.1263926

ISSN: 1664-3224